Tech Center 1600 • Art Units: 1646 1674
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18067085 | Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17366755 | MUSCARINIC ACETYLCHOLINE RECEPTOR BINDING AGENTS AND USES THEREOF | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17410658 | THE FGF19-CHOLESTYRAMINE (F-CME) TEST AS A TWO-STAGE METHOD FOR ROUTINE CANCER SCREENING | Non-Final OA | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 19079960 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | Non-Final OA | EVOLVED BY NATURE, INC. |
| 18240367 | TREATMENT OF SMC MEDIATED DISEASE | Non-Final OA | National University of Singapore |
| 17924307 | METHOD FOR PREPARING ANTIGEN-BINDING UNIT | Non-Final OA | PEKING UNIVERSITY |
| 17782172 | REVERSIBLE CELL DETECTION VIA MHC WITH CONJUGATES HAVING AN ENZYMATICALLY CLEAVABLE DETECTION MOIETY | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 17769188 | METHODS FOR MODULATING LEVEL OF EXPRESSION FROM GENE THERAPY EXPRESSION CASSETTE | Final Rejection | Cornell University |
| 17761274 | COMPOSITIONS AND METHODS COMPRISING IONIZABLE LIPID NANOPARTICLES ENCAPSULATING BARCODED MRNA | Non-Final OA | Cornell University |
| 18048946 | TOOLS AND METHODS FOR EXPRESSION OF MEMBRANE PROTEINS | Final Rejection | Universiteit Gent |
| 18451632 | Methods and Compositions for Treating Cancer | Non-Final OA | Omeros Corporation |
| 17107617 | METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS | Final Rejection | NXERA PHARMA UK LIMITED |
| 18372917 | IMMUNOGLOBULIN FUSION PROTEINS | Non-Final OA | UBI Pharma Inc. (UBIP) |
| 18372942 | METHOD FOR PRODUCING IMMUNOGLOBULIN FUSION PROTEINS | Non-Final OA | UBI Pharma Inc. (UBIP) |
| 18336792 | GLYCOPROTEIN HORMONE RECEPTOR MUTATIONS | Final Rejection | RSR Limited |
| 17777366 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | Non-Final OA | MORPHOSYS GMBH |
| 17531916 | FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | Non-Final OA | Ablynx N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy